Leukemias driven by rearrangements of the lysine methyltransferase 2A (KMT2A, previously known as MLL) gene do not respond well to treatment and have a very poor prognosis (Krivtsov and Armstrong 2007; Milne 2017). This evidence concerns the gene KMT2A and leukemia.